MedTrace Logo

An Efficacy Study of Compound LY2624803 in the Treatment of Patients With Chronic Insomnia

NCT00784875 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 643

Last updated 2012-02-29

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to compare an investigational drug (LY2624803) with placebo and with zolpidem in the treatment of outpatients with chronic insomnia.

Conditions

  • Primary Insomnia
  • Secondary Insomnia

Interventions

DRUG

LY2624803

1 mg, oral capsule, once nightly before bedtime

DRUG

LY2624803

3 mg, oral capsule, once nightly before bedtime

DRUG

Placebo

matching placebo (capsule or tablet), once nightly before bedtime

DRUG

zolpidem

5 or 10 mg, oral tablet, once nightly before bedtime

Sponsors & Collaborators

Principal Investigators

  • Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST) · Eli Lilly and Company

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-10-31
Primary Completion
2010-02-28
Completion
2010-02-28

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00784875 on ClinicalTrials.gov